Abstract:Fibroblast activation protein (FAP) is a promising diagnostic and therapeutic target in various solid tumors. This study aimed to assess the diagnostic efficiency of 68 Ga-labeled FAP inhibitor (FAPI)–04 PET/CT for detecting lymph node metastasis in non–small cell lung cancer (NSCLC) and to investigate the correlation between tumor 68 Ga-FAPI-04 uptake and FAP expression. Methods: We retrospectively enrolled 136 participants with suspected or biopsy-confirmed NSCLC who underwent 68 Ga-FAPI-04 PET/CT for initial staging. The diagnostic performance of 68 Ga-FAPI-04 for the detection of NSCLC was evaluated. The final histopathology or typical imaging features were used as the reference standard. The SUV max and SUV mean , 68 Ga-FAPI–avid tumor volume (FTV), and total lesion FAP expression (TLF) were measured and calculated. FAP immunostaining of tissue specimens was performed. The correlation between 68 Ga-FAPI-04 uptake and FAP expression was assessed using the Spearman correlation coefficient. Results: Ninety-one participants (median age, 65 y [interquartile range, 58–70 y]; 69 men) with NSCLC were finally analyzed. In lesion-based analysis, the diagnostic sensitivity and positive predictive value of 68 Ga-FAPI-04 PET/CT for detection of the primary tumor were 96.70% (88/91) and 100% (88/88), respectively. In station-based analysis, the diagnostic sensitivity, specificity, and accuracy for the detection of lymph node metastasis were 72.00% (18/25), 93.10% (108/116), and 89.36% (126/141), respectively. Tumor 68 Ga-FAPI-04 uptake (SUV max , SUV mean , FTV, and TLF) correlated positively with FAP expression ( r = 0.470, 0.477, 0.582, and 0.608, respectively; all P ≤ 0.001). The volume parameters FTV and TLF correlated strongly with FAP expression in 31 surgical specimens ( r = 0.700 and 0.770, respectively; both P < 0.001). Conclusion: 68 Ga-FAPI-04 PET/CT had excellent diagnostic efficiency for detecting lymph node metastasis, and 68 Ga-FAPI-04 uptake showed a close association with FAP expression in participants with NSCLC.

Langerhans Cell Histiocytosis Showed Intense Uptake of 68Ga-FAPI

Solitary Bone Langerhans Cell Histiocytosis Demonstrated on Multimodality Imaging in an Adult.

Fluorrine-18-fluorodeoxyglucose Positron Emission Tomography/computed Tomography of Adult Liver Langerhans Cell Histiocytosis.

68Ga-FAPI-04 PET/CT Imaging for Fibrous Dysplasia of the Bone

Elevated 68Ga-FAPI Activity in Leiomyosarcoma

Noninvasive imaging of FAP expression using positron emission tomography: A comparative evaluation of a [18F]-labeled glycopeptide-containing FAPI with [18F]FAPI-42

Adult Presentation of Cutaneous Langerhans Cell Histiocytosis

Increased 18F-FAPI uptake in bones and joints of lung cancer patients: characteristics and distributions

68Ga-FAPI PET/CT Detected Non–FDG-Avid Gastric Stromal Tumor

Increased 18F-FAPI-04 Uptake in Vertebral Hemangioma.

Intense 18F-FAPI Uptake in Small Recurrent Lesions of Combined Hepatocellular-Cholangiocarcinoma Negative on 18F-FDG PET/CT

Superior Identification of Metastatic Lesions by 68Ga-FAPI-46 PET/CT Than 18F-FDG PET/CT in Hepatic Solitary Fibrous Tumor

Superior Identification of Metastatic Lesions by 68 Ga-FAPI-46 PET/CT Than 18 F-FDG PET/CT in Hepatic Solitary Fibrous Tumor

18 F-FAPI-42 Versus 18 F-FDG PET/MRI in a Case of Primary Peripheral T-Cell Lymphoma of the Skeletal Muscles

68Ga-FAPI-04 PET/CT Imaging of Mesenteric Aggressive Fibromatosis

Ga-68-FAPI PET/CT Detected Non-FDG-Avid Gastric Stromal Tumor

18F-FAPI for Imaging Metastatic Perivascular Epithelioid Cell Neoplasm

68Ga-FAPI-04 PET/CT Imaging in a Patient With Psoriatic Arthritis

Increased 68Ga-FAPI Uptake in Capillary Hemangiomas in an Adult Patient

68Ga-FAPI-04 PET/CT in Non-Small Cell Lung Cancer: Accurate Evaluation of Lymph Node Metastasis and Correlation with Fibroblast Activation Protein Expression

In Vivo Fibroblast Activation of Systemic Sarcoidosis: A 68Ga-FAPI-04 PET/CT Imaging Study